Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormones (August 2016)

Posted by Matt Breese on Aug 26, 2016

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Data & Analytics, Branding & Marketing

Perspectives on Orphan Drug Reimbursement (Pt. 2)

Posted by Matt Breese on Aug 25, 2016

Earlier this week, we discussed our Perspectives on Orphan Drug Reimbursement. Today, we continue that discussion.

Read More

Topics: Specialty, Industry Trends, Market Access, Payer

Trends that Matter for Pharma Pipeline Development

Posted by Matt Breese on Aug 24, 2016

A collection of engaging infographics from healthcare influencers that reveals trends in drug pipeline development;

There are close to 500 agents in the pipeline to treat cardiovascular diseases, as well as strong pipelines for cancer, diabetes and respiratory diseases, according to IFPMA (International Federation of Pharmaceutical Manufacturers & Associations).

Read More

Topics: Specialty, Industry Trends, Branding & Marketing

Perspectives on Orphan Drug Reimbursement (Pt. 1)

Posted by Matt Breese on Aug 23, 2016

To some, the name itself — orphan disease — suggests a condition that is less noteworthy. Rarely do orphan diseases gain the same kind of notoriety that broader-based diseases, such as breast cancer or HIV, have achieved. Few orphan diseases have designated colored ribbons or national events to gain public support for research and development (R&D) that could lead to new drug therapies.

Read More

Topics: Specialty, Industry Trends, Payer

MMIT Reality Check on Diabetes (August 2016)

Posted by Matt Breese on Aug 19, 2016

MMIT's team analyzes the market access landscape for diabetes treatments in our most recent Reality Check. The following brief highlights some of our key takeaways from the piece.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Perspectives on Biosimilar Marketing (Pt. 2)

Posted by Matt Breese on Aug 18, 2016

Earlier this week, we discussed the growth of biosimilars and biobetters.  Today, we continue that discussion with FDA guidelines and addressing key concerns.

Read More

Topics: Specialty, Industry Trends, Branding & Marketing

Perspectives on Biosimilar Marketing (Pt. 1)

Posted by Matt Breese on Aug 16, 2016

Reducing healthcare costs — or at least effectively managing increased costs — drives many innovations and strategies throughout the industry. In pharma, this goal is one trigger for the growth of biosimilars and biobetters.

Read More

Topics: Industry Trends, Branding & Marketing

Perspectives on Emerging Pharma Competition (Pt. 2)

Posted by Matt Breese on Aug 15, 2016

Last week, we discussed Part 1 of our Perspectives on Emerging Pharma Competition. Today, we continue that discussion, focusing on the biosimilar and biobetter industries of China, South Korea, and Brazil, and how those industries affect the United States pharma landscape.

Read More

Topics: Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on Multiple Sclerosis (Aug 2016)

Posted by Matt Breese on Aug 12, 2016

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends that Matter in Specialty Pharmacy Networks

Posted by Matt Breese on Aug 11, 2016

A collection of engaging infographics from healthcare influencers that reveals trends in specialty pharmacy networks and their growing prevalence in healthcare.

More and more pharmaceutical manufacturers and payers invest in specialty pharmacy networks. With more than 5,000 new medications in the global pipeline and specialty pharmacy accounting for 30% of group health spend, this market provides a massive opportunity to streamline medication fulfillment and adherence. Via Healthesystems

Read More

Topics: Specialty, Industry Trends